These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485 [TBL] [Abstract][Full Text] [Related]
3. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889 [TBL] [Abstract][Full Text] [Related]
4. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. Lagutina IV; Valentine V; Picchione F; Harwood F; Valentine MB; Villarejo-Balcells B; Carvajal JJ; Grosveld GC PLoS Genet; 2015; 11(2):e1004951. PubMed ID: 25659124 [TBL] [Abstract][Full Text] [Related]
5. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Jothi M; Mal M; Keller C; Mal AK Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448 [TBL] [Abstract][Full Text] [Related]
7. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options. Brown RE; Buryanek J; Katz AM; Paz K; Wolff JE Oncotarget; 2016 Jul; 7(29):46263-46272. PubMed ID: 27323832 [TBL] [Abstract][Full Text] [Related]
8. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049 [TBL] [Abstract][Full Text] [Related]
9. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma. Hu Q; Yuan Y; Wang C PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156 [TBL] [Abstract][Full Text] [Related]
10. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
11. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
12. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Marshall AD; Lagutina I; Grosveld GC Cancer Res; 2011 Dec; 71(24):7471-80. PubMed ID: 22037868 [TBL] [Abstract][Full Text] [Related]
13. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
15. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439 [TBL] [Abstract][Full Text] [Related]
16. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target. Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519 [TBL] [Abstract][Full Text] [Related]
17. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma. Marshall AD; van der Ent MA; Grosveld GC Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254 [TBL] [Abstract][Full Text] [Related]
18. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. Zhang Y; Wang C Oncogene; 2011 Aug; 30(32):3549-62. PubMed ID: 21423212 [TBL] [Abstract][Full Text] [Related]
19. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH; Mercado GE; Laé M; Ladanyi M Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015 [TBL] [Abstract][Full Text] [Related]